Parkinson's Disease - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：775頁
文件格式：PDF
價 格：
USD 2,500 (Single-User License)
USD 5,000 (Multi-User License)
USD 7,500 (Global-User License)
USD 5,000 (Multi-User License)
USD 7,500 (Global-User License)
Parkinson's Disease - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Parkinson's Disease - Pipeline Review, H1 2014’, provides an overview of the Parkinson's Disease’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Parkinson's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Parkinson's Disease and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Parkinson's Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Parkinson's Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Parkinson's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Parkinson's Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Parkinson's Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Parkinson's Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Parkinson's Disease - Pipeline Review, H1 2014’, provides an overview of the Parkinson's Disease’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Parkinson's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Parkinson's Disease and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Parkinson's Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Parkinson's Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Parkinson's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Parkinson's Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Parkinson's Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Parkinson's Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
Introduction 9
Parkinson's Disease Overview 10
Therapeutics Development 11
Parkinson's Disease - Therapeutics under Development by Companies 13
Parkinson's Disease - Therapeutics under Investigation by Universities/Institutes 27
Parkinson's Disease - Pipeline Products Glance 31
Parkinson's Disease - Products under Development by Companies 35
Parkinson's Disease - Products under Investigation by Universities/Institutes 51
Parkinson's Disease - Companies Involved in Therapeutics Development 54
Parkinson's Disease - Therapeutics Assessment 220
Drug Profiles 249
Parkinson's Disease - Recent Pipeline Updates 629
Parkinson's Disease - Dormant Projects 722
Parkinson's Disease - Discontinued Products 732
Parkinson's Disease - Product Development Milestones 733
Appendix 742
List of Tables
Number of Products under Development for Parkinson's Disease, H1 2014 43
Number of Products under Development for Parkinson's Disease - Comparative Analysis, H1 2014 44
Number of Products under Development by Companies, H1 2014 46
Number of Products under Development by Companies, H1 2014 (Contd..1) 47
Number of Products under Development by Companies, H1 2014 (Contd..2) 48
Number of Products under Development by Companies, H1 2014 (Contd..3) 49
Number of Products under Development by Companies, H1 2014 (Contd..4) 50
Number of Products under Development by Companies, H1 2014 (Contd..5) 51
Number of Products under Development by Companies, H1 2014 (Contd..6) 52
Number of Products under Development by Companies, H1 2014 (Contd..7) 53
Number of Products under Development by Companies, H1 2014 (Contd..8) 54
Number of Products under Development by Companies, H1 2014 (Contd..9) 55
Number of Products under Development by Companies, H1 2014 (Contd..10) 56
Number of Products under Development by Companies, H1 2014 (Contd..11) 57
Number of Products under Development by Companies, H1 2014 (Contd..12) 58
Number of Products under Investigation by Universities/Institutes, H1 2014 60
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 61
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 62
Comparative Analysis by Late Stage Development, H1 2014 63
Comparative Analysis by Clinical Stage Development, H1 2014 64
Comparative Analysis by Early Stage Development, H1 2014 65
Comparative Analysis by Unknown Stage Development, H1 2014 66
Products under Development by Companies, H1 2014 67
Products under Development by Companies, H1 2014 (Contd..1) 68
Products under Development by Companies, H1 2014 (Contd..2) 69
Products under Development by Companies, H1 2014 (Contd..3) 70
Products under Development by Companies, H1 2014 (Contd..4) 71
Products under Development by Companies, H1 2014 (Contd..5) 72
Products under Development by Companies, H1 2014 (Contd..6) 73
Products under Development by Companies, H1 2014 (Contd..7) 74
Products under Development by Companies, H1 2014 (Contd..8) 75
Products under Development by Companies, H1 2014 (Contd..9) 76
Products under Development by Companies, H1 2014 (Contd..10) 77
Products under Development by Companies, H1 2014 (Contd..11) 78
Products under Development by Companies, H1 2014 (Contd..12) 79
Products under Development by Companies, H1 2014 (Contd..13) 80
Products under Development by Companies, H1 2014 (Contd..14) 81
Products under Development by Companies, H1 2014 (Contd..15) 82
Products under Investigation by Universities/Institutes, H1 2014 83
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 84
Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 85
Parkinson's Disease - Pipeline by Bristol-Myers Squibb Company, H1 2014 86
Parkinson's Disease - Pipeline by Genzyme Corporation, H1 2014 87
Parkinson's Disease - Pipeline by Boehringer Ingelheim GmbH, H1 2014 88
Parkinson's Disease - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2014 89
Parkinson's Disease - Pipeline by Biogen Idec Inc., H1 2014 90
Parkinson's Disease - Pipeline by Allergan, Inc., H1 2014 91
Parkinson's Disease - Pipeline by OXIS International, Inc., H1 2014 92
Parkinson's Disease - Pipeline by NsGene A/S, H1 2014 93
Parkinson's Disease - Pipeline by Sanofi, H1 2014 94
Parkinson's Disease - Pipeline by AstraZeneca PLC, H1 2014 95
Parkinson's Disease - Pipeline by GlaxoSmithKline plc, H1 2014 96
Parkinson's Disease - Pipeline by Genentech, Inc., H1 2014 97
Parkinson's Disease - Pipeline by Merck & Co., Inc., H1 2014 98
Parkinson's Disease - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 99
Parkinson's Disease - Pipeline by Euroscreen S.A., H1 2014 100
Parkinson's Disease - Pipeline by Oxford BioMedica plc, H1 2014 101
Parkinson's Disease - Pipeline by Sangamo BioSciences, Inc., H1 2014 102
Parkinson's Disease - Pipeline by NeuroDerm Ltd., H1 2014 103
Parkinson's Disease - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 104
Parkinson's Disease - Pipeline by Vectura Group plc, H1 2014 105
Parkinson's Disease - Pipeline by XenoPort, Inc., H1 2014 106
Parkinson's Disease - Pipeline by ViaCord, LLC, H1 2014 107
Parkinson's Disease - Pipeline by BioLineRx, Ltd., H1 2014 108
Parkinson's Disease - Pipeline by ApoPharma Inc., H1 2014 109
Parkinson's Disease - Pipeline by Reliance Life Sciences Pvt. Ltd., H1 2014 110
Parkinson's Disease - Pipeline by Aposense Ltd., H1 2014 111
Parkinson's Disease - Pipeline by Novartis AG, H1 2014 112
Parkinson's Disease - Pipeline by EnVivo Pharmaceuticals, H1 2014 113
Parkinson's Disease - Pipeline by Depomed, Inc., H1 2014 114
Parkinson's Disease - Pipeline by Elan Corporation, plc, H1 2014 115
Parkinson's Disease - Pipeline by H. Lundbeck A/S, H1 2014 116
Parkinson's Disease - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2014 117
Parkinson's Disease - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2014 118
Parkinson's Disease - Pipeline by Orion Oyj, H1 2014 119
Parkinson's Disease - Pipeline by Pfizer Inc., H1 2014 120
Parkinson's Disease - Pipeline by Sigma-Tau S.p.A., H1 2014 121
Parkinson's Disease - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 122
Parkinson's Disease - Pipeline by UCB S.A., H1 2014 123
Parkinson's Disease - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2014 124
Parkinson's Disease - Pipeline by Impax Laboratories, Inc., H1 2014 125
Parkinson's Disease - Pipeline by Vernalis plc., H1 2014 126
Parkinson's Disease - Pipeline by OPKO Health, Inc., H1 2014 127
Parkinson's Disease - Pipeline by NuPathe Inc., H1 2014 128
Parkinson's Disease - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2014 129
Parkinson's Disease - Pipeline by Addex Therapeutics, H1 2014 130
Parkinson's Disease - Pipeline by Harbor Therapeutics, Inc., H1 2014 131
Parkinson's Disease - Pipeline by Imugene Limited, H1 2014 132
Parkinson's Disease - Pipeline by Neuralstem, Inc., H1 2014 133
Parkinson's Disease - Pipeline by Amicus Therapeutics, Inc., H1 2014 134
Parkinson's Disease - Pipeline by International Stem Cell Corporation, H1 2014 135
Parkinson's Disease - Pipeline by Mesoblast Limited, H1 2014 136
Parkinson's Disease - Pipeline by Bionomics Limited, H1 2014 137
Parkinson's Disease - Pipeline by Neuren Pharmaceuticals Limited, H1 2014 138
Parkinson's Disease - Pipeline by NeuroSearch A/S, H1 2014 139
Parkinson's Disease - Pipeline by Cortex Pharmaceuticals, Inc., H1 2014 140
Parkinson's Disease - Pipeline by Acadia Pharmaceuticals Inc., H1 2014 141
Parkinson's Disease - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2014 142
Parkinson's Disease - Pipeline by ProteoTech, Inc., H1 2014 143
Parkinson's Disease - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H1 2014 144
Parkinson's Disease - Pipeline by Repligen Corporation, H1 2014 145
Parkinson's Disease - Pipeline by Prana Biotechnology Limited, H1 2014 146
Parkinson's Disease - Pipeline by AnGes MG, Inc., H1 2014 147
Parkinson's Disease - Pipeline by Suven Life Sciences Ltd., H1 2014 148
Parkinson's Disease - Pipeline by CrystalGenomics, Inc., H1 2014 149
Parkinson's Disease - Pipeline by Newron Pharmaceuticals S.p.A., H1 2014 150
Parkinson's Disease - Pipeline by Huons Co., Ltd., H1 2014 151
Parkinson's Disease - Pipeline by Raptor Pharmaceuticals Corp., H1 2014 152
Parkinson's Disease - Pipeline by e-Therapeutics plc, H1 2014 153
Parkinson's Disease - Pipeline by tesa Labtec GmbH, H1 2014 154
Parkinson's Disease - Pipeline by Oryzon Genomics S.A., H1 2014 155
Parkinson's Disease - Pipeline by M et P Pharma AG, H1 2014 156
Parkinson's Disease - Pipeline by TauRx Therapeutics Ltd, H1 2014 157
Parkinson's Disease - Pipeline by AFFiRiS AG, H1 2014 158
Parkinson's Disease - Pipeline by Accera, Inc., H1 2014 159
Parkinson's Disease - Pipeline by Advinus Therapeutics Ltd., H1 2014 160
Parkinson's Disease - Pipeline by Scynexis, Inc., H1 2014 161
Parkinson's Disease - Pipeline by Chipscreen Biosciences Ltd, H1 2014 162
Parkinson's Disease - Pipeline by Upsher-Smith Laboratories, Inc., H1 2014 163
Parkinson's Disease - Pipeline by Osmotica Pharmaceutical Corp., H1 2014 164
Parkinson's Disease - Pipeline by Snowdon Inc., H1 2014 165
Parkinson's Disease - Pipeline by Domain Therapeutics SA, H1 2014 166
Parkinson's Disease - Pipeline by reMYND, H1 2014 167
Parkinson's Disease - Pipeline by Abiogen Pharma S.p.A., H1 2014 168
Parkinson's Disease - Pipeline by Motac Neuroscience Ltd, H1 2014 169
Parkinson's Disease - Pipeline by Neuroprofile GmbH, H1 2014 170
Parkinson's Disease - Pipeline by Wellstat Therapeutics Corporation, H1 2014 171
Parkinson's Disease - Pipeline by Oncodesign SA, H1 2014 172
Parkinson's Disease - Pipeline by Trophos SA, H1 2014 173
Parkinson's Disease - Pipeline by Curemark, LLC, H1 2014 174
Parkinson's Disease - Pipeline by Intec Pharma ltd., H1 2014 175
Parkinson's Disease - Pipeline by InterMed Discovery GmbH, H1 2014 176
Parkinson's Disease - Pipeline by Medeia Therapeutics Ltd., H1 2014 177
Parkinson's Disease - Pipeline by MedGenesis Therapeutix Inc., H1 2014 178
Parkinson's Disease - Pipeline by AngioChem Inc., H1 2014 179
Parkinson's Disease - Pipeline by Metabolic Solutions Development Co., H1 2014 180
Parkinson's Disease - Pipeline by Trevena, Inc., H1 2014 181
Parkinson's Disease - Pipeline by Fabre-Kramer Pharmaceuticals, Inc., H1 2014 182
Parkinson's Disease - Pipeline by BioArctic Neuroscience AB, H1 2014 183
Parkinson's Disease - Pipeline by Indus Biotech Private Limited, H1 2014 184
Parkinson's Disease - Pipeline by Affichem, H1 2014 185
Parkinson's Disease - Pipeline by QR Pharma, Inc., H1 2014 186
Parkinson's Disease - Pipeline by NeuroNascent, Inc., H1 2014 187
Parkinson's Disease - Pipeline by KineMed, Inc., H1 2014 188
Parkinson's Disease - Pipeline by Dart NeuroScience LLC, H1 2014 189
Parkinson's Disease - Pipeline by QRxPharma Limited, H1 2014 190
Parkinson's Disease - Pipeline by Omeros Corporation, H1 2014 191
Parkinson's Disease - Pipeline by Intra-Cellular Therapies, Inc., H1 2014 192
Parkinson's Disease - Pipeline by Targacept, Inc., H1 2014 193
Parkinson's Disease - Pipeline by Obio Pharmaceutical Holdings Limited, H1 2014 194
Parkinson's Disease - Pipeline by Cellceutix Corporation, H1 2014 195
Parkinson's Disease - Pipeline by SanBio, Inc., H1 2014 196
Parkinson's Disease - Pipeline by Tautatis Incorporated, H1 2014 197
Parkinson's Disease - Pipeline by Proteostasis Therapeutics, Inc., H1 2014 198
Parkinson's Disease - Pipeline by M's Science Corporation, H1 2014 199
Parkinson's Disease - Pipeline by Stelic Institute & Co., H1 2014 200
Parkinson's Disease - Pipeline by Cynapsus Therapeutics, Inc., H1 2014 201
Parkinson's Disease - Pipeline by Bial - Portela & Ca, S.A., H1 2014 202
Parkinson's Disease - Pipeline by Pharnext SAS, H1 2014 203
Parkinson's Disease - Pipeline by Heptares Therapeutics Ltd., H1 2014 204
Parkinson's Disease - Pipeline by Ascendis Pharma A/S, H1 2014 205
Parkinson's Disease - Pipeline by Signum Biosciences, Inc., H1 2014 206
Parkinson's Disease - Pipeline by Neuraltus Pharmaceuticals, Inc., H1 2014 207
Parkinson's Disease - Pipeline by RhinoCyte, Inc., H1 2014 208
Parkinson's Disease - Pipeline by ArmaGen Technologies, Inc., H1 2014 209
Parkinson's Disease - Pipeline by Edison Pharmaceuticals, Inc., H1 2014 210
Parkinson's Disease - Pipeline by CHA Bio & Diostech Co., Ltd., H1 2014 211
Parkinson's Disease - Pipeline by Gene Solutions LLC, H1 2014 212
Parkinson's Disease - Pipeline by Clera Inc., H1 2014 213
Parkinson's Disease - Pipeline by Genosco, H1 2014 214
Parkinson's Disease - Pipeline by Varinel, Inc., H1 2014 216
Parkinson's Disease - Pipeline by Luye Pharma Group Ltd., H1 2014 217
Parkinson's Disease - Pipeline by Promentis Pharmaceuticals, Inc., H1 2014 218
Parkinson's Disease - Pipeline by iPierian, Inc, H1 2014 219
Parkinson's Disease - Pipeline by SignPath Pharma Inc, H1 2014 220
Parkinson's Disease - Pipeline by STATegics, Inc., H1 2014 221
Parkinson's Disease - Pipeline by PharmaNeuroBoost NV, H1 2014 222
Parkinson's Disease - Pipeline by Neuron Biopharma SA, H1 2014 223
Parkinson's Disease - Pipeline by Selvita S.A, H1 2014 224
Parkinson's Disease - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2014 225
Parkinson's Disease - Pipeline by Cell Cure Neurosciences, Ltd., H1 2014 226
Parkinson's Disease - Pipeline by VivaCell Biotechnology Espana S.L., H1 2014 227
Parkinson's Disease - Pipeline by Genervon Biopharmaceuticals, LLC, H1 2014 228
Parkinson's Disease - Pipeline by Civitas Therapeutics, Inc., H1 2014 229
Parkinson's Disease - Pipeline by Lead Discovery Center GmbH, H1 2014 230
Parkinson's Disease - Pipeline by NeuroPhage Pharmaceuticals, Inc., H1 2014 231
Parkinson's Disease - Pipeline by Hermo Pharma Oy, H1 2014 232
Parkinson's Disease - Pipeline by Bionure, H1 2014 233
Parkinson's Disease - Pipeline by Pharma Two B Ltd., H1 2014 234
Parkinson's Disease - Pipeline by Serina Therapeutics, Inc., H1 2014 235
Parkinson's Disease - Pipeline by Valens Therapeutics, Inc., H1 2014 236
Parkinson's Disease - Pipeline by Arrien Pharmaceuticals, LLC, H1 2014 237
Parkinson's Disease - Pipeline by CalAsia Pharmaceuticals, Inc., H1 2014 238
Parkinson's Disease - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2014 239
Parkinson's Disease - Pipeline by Io Therapeutics, Inc., H1 2014 240
Parkinson's Disease - Pipeline by Chronos Therapeutics Limited, H1 2014 241
Parkinson's Disease - Pipeline by UniQure BV, H1 2014 242
Parkinson's Disease - Pipeline by nLife Therapeutics, S.L., H1 2014 243
Parkinson's Disease - Pipeline by Neurodyn Inc., H1 2014 244
Parkinson's Disease - Pipeline by AbbVie Inc., H1 2014 245
Parkinson's Disease - Pipeline by Prexton Therapeutics SA, H1 2014 246
Parkinson's Disease - Pipeline by Angita B.V., H1 2014 247
Parkinson's Disease - Pipeline by Inventiva SAS, H1 2014 248
Parkinson's Disease - Pipeline by Netherlands Translational Research Center B.V., H1 2014 249
Parkinson's Disease - Pipeline by Neurolixis Inc., H1 2014 250
Parkinson's Disease - Pipeline by Bionature E.A. Ltd., H1 2014 251
Assessment by Monotherapy Products, H1 2014 252
Assessment by Combination Products, H1 2014 253
Number of Products by Stage and Target, H1 2014 256
Number of Products by Stage and Mechanism of Action, H1 2014 266
Number of Products by Stage and Route of Administration, H1 2014 277
Number of Products by Stage and Molecule Type, H1 2014 280
Parkinson's Disease Therapeutics - Recent Pipeline Updates, H1 2014 661
Parkinson's Disease - Dormant Projects, H1 2014 754
Parkinson's Disease - Dormant Projects (Contd..1), H1 2014 755
Parkinson's Disease - Dormant Projects (Contd..2), H1 2014 756
Parkinson's Disease - Dormant Projects (Contd..3), H1 2014 757
Parkinson's Disease - Dormant Projects (Contd..4), H1 2014 758
Parkinson's Disease - Dormant Projects (Contd..5), H1 2014 759
Parkinson's Disease - Dormant Projects (Contd..6), H1 2014 760
Parkinson's Disease - Dormant Projects (Contd..7), H1 2014 761
Parkinson's Disease - Dormant Projects (Contd..8), H1 2014 762
Parkinson's Disease - Dormant Projects (Contd..9), H1 2014 763
Parkinson's Disease - Discontinued Products, H1 2014 764
List of Figures
Number of Products under Development for Parkinson's Disease, H1 2014 43
Number of Products under Development for Parkinson's Disease - Comparative Analysis, H1 2014 44
Number of Products under Development by Companies, H1 2014 45
Number of Products under Investigation by Universities/Institutes, H1 2014 59
Comparative Analysis by Late Stage Development, H1 2014 63
Comparative Analysis by Clinical Stage Development, H1 2014 64
Comparative Analysis by Early Stage Products, H1 2014 65
Comparative Analysis by Unknown Stage Development, H1 2014 66
Assessment by Monotherapy Products, H1 2014 252
Assessment by Combination Products, H1 2014 253
Number of Products by Top 10 Target, H1 2014 254
Number of Products by Stage and Top 10 Target, H1 2014 255
Number of Products by Top 10 Mechanism of Action, H1 2014 264
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 265
Number of Products by Top 10 Route of Administration, H1 2014 275
Number of Products by Stage and Top 10 Route of Administration, H1 2014 276
Number of Products by Top 10 Molecule Type, H1 2014 278
Number of Products by Stage and Top 10 Molecule Type, H1 2014 279
Table of Contents 2
Introduction 9
Parkinson's Disease Overview 10
Therapeutics Development 11
Parkinson's Disease - Therapeutics under Development by Companies 13
Parkinson's Disease - Therapeutics under Investigation by Universities/Institutes 27
Parkinson's Disease - Pipeline Products Glance 31
Parkinson's Disease - Products under Development by Companies 35
Parkinson's Disease - Products under Investigation by Universities/Institutes 51
Parkinson's Disease - Companies Involved in Therapeutics Development 54
Parkinson's Disease - Therapeutics Assessment 220
Drug Profiles 249
Parkinson's Disease - Recent Pipeline Updates 629
Parkinson's Disease - Dormant Projects 722
Parkinson's Disease - Discontinued Products 732
Parkinson's Disease - Product Development Milestones 733
Appendix 742
List of Tables
Number of Products under Development for Parkinson's Disease, H1 2014 43
Number of Products under Development for Parkinson's Disease - Comparative Analysis, H1 2014 44
Number of Products under Development by Companies, H1 2014 46
Number of Products under Development by Companies, H1 2014 (Contd..1) 47
Number of Products under Development by Companies, H1 2014 (Contd..2) 48
Number of Products under Development by Companies, H1 2014 (Contd..3) 49
Number of Products under Development by Companies, H1 2014 (Contd..4) 50
Number of Products under Development by Companies, H1 2014 (Contd..5) 51
Number of Products under Development by Companies, H1 2014 (Contd..6) 52
Number of Products under Development by Companies, H1 2014 (Contd..7) 53
Number of Products under Development by Companies, H1 2014 (Contd..8) 54
Number of Products under Development by Companies, H1 2014 (Contd..9) 55
Number of Products under Development by Companies, H1 2014 (Contd..10) 56
Number of Products under Development by Companies, H1 2014 (Contd..11) 57
Number of Products under Development by Companies, H1 2014 (Contd..12) 58
Number of Products under Investigation by Universities/Institutes, H1 2014 60
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 61
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 62
Comparative Analysis by Late Stage Development, H1 2014 63
Comparative Analysis by Clinical Stage Development, H1 2014 64
Comparative Analysis by Early Stage Development, H1 2014 65
Comparative Analysis by Unknown Stage Development, H1 2014 66
Products under Development by Companies, H1 2014 67
Products under Development by Companies, H1 2014 (Contd..1) 68
Products under Development by Companies, H1 2014 (Contd..2) 69
Products under Development by Companies, H1 2014 (Contd..3) 70
Products under Development by Companies, H1 2014 (Contd..4) 71
Products under Development by Companies, H1 2014 (Contd..5) 72
Products under Development by Companies, H1 2014 (Contd..6) 73
Products under Development by Companies, H1 2014 (Contd..7) 74
Products under Development by Companies, H1 2014 (Contd..8) 75
Products under Development by Companies, H1 2014 (Contd..9) 76
Products under Development by Companies, H1 2014 (Contd..10) 77
Products under Development by Companies, H1 2014 (Contd..11) 78
Products under Development by Companies, H1 2014 (Contd..12) 79
Products under Development by Companies, H1 2014 (Contd..13) 80
Products under Development by Companies, H1 2014 (Contd..14) 81
Products under Development by Companies, H1 2014 (Contd..15) 82
Products under Investigation by Universities/Institutes, H1 2014 83
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 84
Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 85
Parkinson's Disease - Pipeline by Bristol-Myers Squibb Company, H1 2014 86
Parkinson's Disease - Pipeline by Genzyme Corporation, H1 2014 87
Parkinson's Disease - Pipeline by Boehringer Ingelheim GmbH, H1 2014 88
Parkinson's Disease - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2014 89
Parkinson's Disease - Pipeline by Biogen Idec Inc., H1 2014 90
Parkinson's Disease - Pipeline by Allergan, Inc., H1 2014 91
Parkinson's Disease - Pipeline by OXIS International, Inc., H1 2014 92
Parkinson's Disease - Pipeline by NsGene A/S, H1 2014 93
Parkinson's Disease - Pipeline by Sanofi, H1 2014 94
Parkinson's Disease - Pipeline by AstraZeneca PLC, H1 2014 95
Parkinson's Disease - Pipeline by GlaxoSmithKline plc, H1 2014 96
Parkinson's Disease - Pipeline by Genentech, Inc., H1 2014 97
Parkinson's Disease - Pipeline by Merck & Co., Inc., H1 2014 98
Parkinson's Disease - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 99
Parkinson's Disease - Pipeline by Euroscreen S.A., H1 2014 100
Parkinson's Disease - Pipeline by Oxford BioMedica plc, H1 2014 101
Parkinson's Disease - Pipeline by Sangamo BioSciences, Inc., H1 2014 102
Parkinson's Disease - Pipeline by NeuroDerm Ltd., H1 2014 103
Parkinson's Disease - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 104
Parkinson's Disease - Pipeline by Vectura Group plc, H1 2014 105
Parkinson's Disease - Pipeline by XenoPort, Inc., H1 2014 106
Parkinson's Disease - Pipeline by ViaCord, LLC, H1 2014 107
Parkinson's Disease - Pipeline by BioLineRx, Ltd., H1 2014 108
Parkinson's Disease - Pipeline by ApoPharma Inc., H1 2014 109
Parkinson's Disease - Pipeline by Reliance Life Sciences Pvt. Ltd., H1 2014 110
Parkinson's Disease - Pipeline by Aposense Ltd., H1 2014 111
Parkinson's Disease - Pipeline by Novartis AG, H1 2014 112
Parkinson's Disease - Pipeline by EnVivo Pharmaceuticals, H1 2014 113
Parkinson's Disease - Pipeline by Depomed, Inc., H1 2014 114
Parkinson's Disease - Pipeline by Elan Corporation, plc, H1 2014 115
Parkinson's Disease - Pipeline by H. Lundbeck A/S, H1 2014 116
Parkinson's Disease - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2014 117
Parkinson's Disease - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2014 118
Parkinson's Disease - Pipeline by Orion Oyj, H1 2014 119
Parkinson's Disease - Pipeline by Pfizer Inc., H1 2014 120
Parkinson's Disease - Pipeline by Sigma-Tau S.p.A., H1 2014 121
Parkinson's Disease - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 122
Parkinson's Disease - Pipeline by UCB S.A., H1 2014 123
Parkinson's Disease - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2014 124
Parkinson's Disease - Pipeline by Impax Laboratories, Inc., H1 2014 125
Parkinson's Disease - Pipeline by Vernalis plc., H1 2014 126
Parkinson's Disease - Pipeline by OPKO Health, Inc., H1 2014 127
Parkinson's Disease - Pipeline by NuPathe Inc., H1 2014 128
Parkinson's Disease - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2014 129
Parkinson's Disease - Pipeline by Addex Therapeutics, H1 2014 130
Parkinson's Disease - Pipeline by Harbor Therapeutics, Inc., H1 2014 131
Parkinson's Disease - Pipeline by Imugene Limited, H1 2014 132
Parkinson's Disease - Pipeline by Neuralstem, Inc., H1 2014 133
Parkinson's Disease - Pipeline by Amicus Therapeutics, Inc., H1 2014 134
Parkinson's Disease - Pipeline by International Stem Cell Corporation, H1 2014 135
Parkinson's Disease - Pipeline by Mesoblast Limited, H1 2014 136
Parkinson's Disease - Pipeline by Bionomics Limited, H1 2014 137
Parkinson's Disease - Pipeline by Neuren Pharmaceuticals Limited, H1 2014 138
Parkinson's Disease - Pipeline by NeuroSearch A/S, H1 2014 139
Parkinson's Disease - Pipeline by Cortex Pharmaceuticals, Inc., H1 2014 140
Parkinson's Disease - Pipeline by Acadia Pharmaceuticals Inc., H1 2014 141
Parkinson's Disease - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2014 142
Parkinson's Disease - Pipeline by ProteoTech, Inc., H1 2014 143
Parkinson's Disease - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H1 2014 144
Parkinson's Disease - Pipeline by Repligen Corporation, H1 2014 145
Parkinson's Disease - Pipeline by Prana Biotechnology Limited, H1 2014 146
Parkinson's Disease - Pipeline by AnGes MG, Inc., H1 2014 147
Parkinson's Disease - Pipeline by Suven Life Sciences Ltd., H1 2014 148
Parkinson's Disease - Pipeline by CrystalGenomics, Inc., H1 2014 149
Parkinson's Disease - Pipeline by Newron Pharmaceuticals S.p.A., H1 2014 150
Parkinson's Disease - Pipeline by Huons Co., Ltd., H1 2014 151
Parkinson's Disease - Pipeline by Raptor Pharmaceuticals Corp., H1 2014 152
Parkinson's Disease - Pipeline by e-Therapeutics plc, H1 2014 153
Parkinson's Disease - Pipeline by tesa Labtec GmbH, H1 2014 154
Parkinson's Disease - Pipeline by Oryzon Genomics S.A., H1 2014 155
Parkinson's Disease - Pipeline by M et P Pharma AG, H1 2014 156
Parkinson's Disease - Pipeline by TauRx Therapeutics Ltd, H1 2014 157
Parkinson's Disease - Pipeline by AFFiRiS AG, H1 2014 158
Parkinson's Disease - Pipeline by Accera, Inc., H1 2014 159
Parkinson's Disease - Pipeline by Advinus Therapeutics Ltd., H1 2014 160
Parkinson's Disease - Pipeline by Scynexis, Inc., H1 2014 161
Parkinson's Disease - Pipeline by Chipscreen Biosciences Ltd, H1 2014 162
Parkinson's Disease - Pipeline by Upsher-Smith Laboratories, Inc., H1 2014 163
Parkinson's Disease - Pipeline by Osmotica Pharmaceutical Corp., H1 2014 164
Parkinson's Disease - Pipeline by Snowdon Inc., H1 2014 165
Parkinson's Disease - Pipeline by Domain Therapeutics SA, H1 2014 166
Parkinson's Disease - Pipeline by reMYND, H1 2014 167
Parkinson's Disease - Pipeline by Abiogen Pharma S.p.A., H1 2014 168
Parkinson's Disease - Pipeline by Motac Neuroscience Ltd, H1 2014 169
Parkinson's Disease - Pipeline by Neuroprofile GmbH, H1 2014 170
Parkinson's Disease - Pipeline by Wellstat Therapeutics Corporation, H1 2014 171
Parkinson's Disease - Pipeline by Oncodesign SA, H1 2014 172
Parkinson's Disease - Pipeline by Trophos SA, H1 2014 173
Parkinson's Disease - Pipeline by Curemark, LLC, H1 2014 174
Parkinson's Disease - Pipeline by Intec Pharma ltd., H1 2014 175
Parkinson's Disease - Pipeline by InterMed Discovery GmbH, H1 2014 176
Parkinson's Disease - Pipeline by Medeia Therapeutics Ltd., H1 2014 177
Parkinson's Disease - Pipeline by MedGenesis Therapeutix Inc., H1 2014 178
Parkinson's Disease - Pipeline by AngioChem Inc., H1 2014 179
Parkinson's Disease - Pipeline by Metabolic Solutions Development Co., H1 2014 180
Parkinson's Disease - Pipeline by Trevena, Inc., H1 2014 181
Parkinson's Disease - Pipeline by Fabre-Kramer Pharmaceuticals, Inc., H1 2014 182
Parkinson's Disease - Pipeline by BioArctic Neuroscience AB, H1 2014 183
Parkinson's Disease - Pipeline by Indus Biotech Private Limited, H1 2014 184
Parkinson's Disease - Pipeline by Affichem, H1 2014 185
Parkinson's Disease - Pipeline by QR Pharma, Inc., H1 2014 186
Parkinson's Disease - Pipeline by NeuroNascent, Inc., H1 2014 187
Parkinson's Disease - Pipeline by KineMed, Inc., H1 2014 188
Parkinson's Disease - Pipeline by Dart NeuroScience LLC, H1 2014 189
Parkinson's Disease - Pipeline by QRxPharma Limited, H1 2014 190
Parkinson's Disease - Pipeline by Omeros Corporation, H1 2014 191
Parkinson's Disease - Pipeline by Intra-Cellular Therapies, Inc., H1 2014 192
Parkinson's Disease - Pipeline by Targacept, Inc., H1 2014 193
Parkinson's Disease - Pipeline by Obio Pharmaceutical Holdings Limited, H1 2014 194
Parkinson's Disease - Pipeline by Cellceutix Corporation, H1 2014 195
Parkinson's Disease - Pipeline by SanBio, Inc., H1 2014 196
Parkinson's Disease - Pipeline by Tautatis Incorporated, H1 2014 197
Parkinson's Disease - Pipeline by Proteostasis Therapeutics, Inc., H1 2014 198
Parkinson's Disease - Pipeline by M's Science Corporation, H1 2014 199
Parkinson's Disease - Pipeline by Stelic Institute & Co., H1 2014 200
Parkinson's Disease - Pipeline by Cynapsus Therapeutics, Inc., H1 2014 201
Parkinson's Disease - Pipeline by Bial - Portela & Ca, S.A., H1 2014 202
Parkinson's Disease - Pipeline by Pharnext SAS, H1 2014 203
Parkinson's Disease - Pipeline by Heptares Therapeutics Ltd., H1 2014 204
Parkinson's Disease - Pipeline by Ascendis Pharma A/S, H1 2014 205
Parkinson's Disease - Pipeline by Signum Biosciences, Inc., H1 2014 206
Parkinson's Disease - Pipeline by Neuraltus Pharmaceuticals, Inc., H1 2014 207
Parkinson's Disease - Pipeline by RhinoCyte, Inc., H1 2014 208
Parkinson's Disease - Pipeline by ArmaGen Technologies, Inc., H1 2014 209
Parkinson's Disease - Pipeline by Edison Pharmaceuticals, Inc., H1 2014 210
Parkinson's Disease - Pipeline by CHA Bio & Diostech Co., Ltd., H1 2014 211
Parkinson's Disease - Pipeline by Gene Solutions LLC, H1 2014 212
Parkinson's Disease - Pipeline by Clera Inc., H1 2014 213
Parkinson's Disease - Pipeline by Genosco, H1 2014 214
Parkinson's Disease - Pipeline by Varinel, Inc., H1 2014 216
Parkinson's Disease - Pipeline by Luye Pharma Group Ltd., H1 2014 217
Parkinson's Disease - Pipeline by Promentis Pharmaceuticals, Inc., H1 2014 218
Parkinson's Disease - Pipeline by iPierian, Inc, H1 2014 219
Parkinson's Disease - Pipeline by SignPath Pharma Inc, H1 2014 220
Parkinson's Disease - Pipeline by STATegics, Inc., H1 2014 221
Parkinson's Disease - Pipeline by PharmaNeuroBoost NV, H1 2014 222
Parkinson's Disease - Pipeline by Neuron Biopharma SA, H1 2014 223
Parkinson's Disease - Pipeline by Selvita S.A, H1 2014 224
Parkinson's Disease - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2014 225
Parkinson's Disease - Pipeline by Cell Cure Neurosciences, Ltd., H1 2014 226
Parkinson's Disease - Pipeline by VivaCell Biotechnology Espana S.L., H1 2014 227
Parkinson's Disease - Pipeline by Genervon Biopharmaceuticals, LLC, H1 2014 228
Parkinson's Disease - Pipeline by Civitas Therapeutics, Inc., H1 2014 229
Parkinson's Disease - Pipeline by Lead Discovery Center GmbH, H1 2014 230
Parkinson's Disease - Pipeline by NeuroPhage Pharmaceuticals, Inc., H1 2014 231
Parkinson's Disease - Pipeline by Hermo Pharma Oy, H1 2014 232
Parkinson's Disease - Pipeline by Bionure, H1 2014 233
Parkinson's Disease - Pipeline by Pharma Two B Ltd., H1 2014 234
Parkinson's Disease - Pipeline by Serina Therapeutics, Inc., H1 2014 235
Parkinson's Disease - Pipeline by Valens Therapeutics, Inc., H1 2014 236
Parkinson's Disease - Pipeline by Arrien Pharmaceuticals, LLC, H1 2014 237
Parkinson's Disease - Pipeline by CalAsia Pharmaceuticals, Inc., H1 2014 238
Parkinson's Disease - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2014 239
Parkinson's Disease - Pipeline by Io Therapeutics, Inc., H1 2014 240
Parkinson's Disease - Pipeline by Chronos Therapeutics Limited, H1 2014 241
Parkinson's Disease - Pipeline by UniQure BV, H1 2014 242
Parkinson's Disease - Pipeline by nLife Therapeutics, S.L., H1 2014 243
Parkinson's Disease - Pipeline by Neurodyn Inc., H1 2014 244
Parkinson's Disease - Pipeline by AbbVie Inc., H1 2014 245
Parkinson's Disease - Pipeline by Prexton Therapeutics SA, H1 2014 246
Parkinson's Disease - Pipeline by Angita B.V., H1 2014 247
Parkinson's Disease - Pipeline by Inventiva SAS, H1 2014 248
Parkinson's Disease - Pipeline by Netherlands Translational Research Center B.V., H1 2014 249
Parkinson's Disease - Pipeline by Neurolixis Inc., H1 2014 250
Parkinson's Disease - Pipeline by Bionature E.A. Ltd., H1 2014 251
Assessment by Monotherapy Products, H1 2014 252
Assessment by Combination Products, H1 2014 253
Number of Products by Stage and Target, H1 2014 256
Number of Products by Stage and Mechanism of Action, H1 2014 266
Number of Products by Stage and Route of Administration, H1 2014 277
Number of Products by Stage and Molecule Type, H1 2014 280
Parkinson's Disease Therapeutics - Recent Pipeline Updates, H1 2014 661
Parkinson's Disease - Dormant Projects, H1 2014 754
Parkinson's Disease - Dormant Projects (Contd..1), H1 2014 755
Parkinson's Disease - Dormant Projects (Contd..2), H1 2014 756
Parkinson's Disease - Dormant Projects (Contd..3), H1 2014 757
Parkinson's Disease - Dormant Projects (Contd..4), H1 2014 758
Parkinson's Disease - Dormant Projects (Contd..5), H1 2014 759
Parkinson's Disease - Dormant Projects (Contd..6), H1 2014 760
Parkinson's Disease - Dormant Projects (Contd..7), H1 2014 761
Parkinson's Disease - Dormant Projects (Contd..8), H1 2014 762
Parkinson's Disease - Dormant Projects (Contd..9), H1 2014 763
Parkinson's Disease - Discontinued Products, H1 2014 764
List of Figures
Number of Products under Development for Parkinson's Disease, H1 2014 43
Number of Products under Development for Parkinson's Disease - Comparative Analysis, H1 2014 44
Number of Products under Development by Companies, H1 2014 45
Number of Products under Investigation by Universities/Institutes, H1 2014 59
Comparative Analysis by Late Stage Development, H1 2014 63
Comparative Analysis by Clinical Stage Development, H1 2014 64
Comparative Analysis by Early Stage Products, H1 2014 65
Comparative Analysis by Unknown Stage Development, H1 2014 66
Assessment by Monotherapy Products, H1 2014 252
Assessment by Combination Products, H1 2014 253
Number of Products by Top 10 Target, H1 2014 254
Number of Products by Stage and Top 10 Target, H1 2014 255
Number of Products by Top 10 Mechanism of Action, H1 2014 264
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 265
Number of Products by Top 10 Route of Administration, H1 2014 275
Number of Products by Stage and Top 10 Route of Administration, H1 2014 276
Number of Products by Top 10 Molecule Type, H1 2014 278
Number of Products by Stage and Top 10 Molecule Type, H1 2014 279
